Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + albumin paclitaxel with or without cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2500114647Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of tislelizumab, nab-paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Pathological complete response rate (pCR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tislelizumabnab-paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500114647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114647.